74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Medpace Holdings Inc
Closed
SectorHealthcare
302.47 3.93
Overview
Share price change
24h
Min
284.67
Max
303.22
Income | 21M 117M |
|---|---|
Sales | 3.3M 537M |
P/E Sector Avg | 22.077 57.333 |
EPS | 3.67 |
Profit margin | 21.808 |
Employees | 5,900 |
EBITDA | -916K 125M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +2.68% upside |
Next Earnings | 21 Jul 2025 |
|---|
Market Cap | 9B |
|---|---|
Previous open | 298.54 |
Previous close | 302.47 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Medpace Holdings Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Medpace Holdings Inc Forecast
Price Target
By TipRanks
2.68% upside
12 Months Forecast
Average 311 USD 2.68%
High 355 USD
Low 283 USD
Based on 7 Wall Street analysts offering 12 month price targets forMedpace Holdings Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
